Skip to main content
S

SAPPORO CLINICAL LABORATORY INC. — Investor Relations & Filings

Ticker · 9776 ISIN · JP3321100004 T Human health and social work activities
Open in API
Filings indexed 60 across all filing types
Latest filing 2025-11-10 Regulatory Filings
Country JP Japan
Listing T 9776

About SAPPORO CLINICAL LABORATORY INC.

https://www.saturin.co.jp/

SAPPORO CLINICAL LABORATORY INC. is a comprehensive healthcare services company primarily engaged in clinical laboratory testing and the operation of dispensing pharmacies. The company provides a wide array of testing services to medical institutions, including clinical and pathological examinations, biochemical and hematological analyses, microbiological assessments, and genetic testing. Additional services cover food hygiene and environmental inspections, radiation management, and electrocardiographic examinations. In addition to its laboratory operations, the company runs a network of dispensing pharmacies. It also offers support services for clinic openings, focusing on supporting regional healthcare with an emphasis on quality and safety management.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly cites '金融商品取引法第24条の５の２第１項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification confirming the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like a semi-annual report. H1 62
2025-11-10 Japanese
半期報告書－第62期(2025/04/01－2025/09/30)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Sapporo Clinical Laboratory Inc. under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements (balance sheets, income statements, cash flow statements) for the interim period ending September 30, 2025. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2026
2025-11-10 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted because resolutions were passed at the "当社第61回定時株主総会" (The 61st Annual General Meeting of Shareholders). Section 2 details the resolutions, including dividend approval (剰余金処分の件), amendment of articles of incorporation (定款一部変更の件), and election of directors (取締役７名選任の件), along with the voting results. This content directly relates to the outcomes and proceedings of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2025-06-26 Japanese
内部統制報告書－第61期(2024/04/01－2025/03/31)
Governance Information Classification · 1% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly states its legal basis as "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). It details the scope, criteria (based on the Financial Accounting Standards Board's framework), assessment date (March 31, 2025), and concludes that the internal controls over financial reporting are effective. This structure and content are characteristic of an Audit Report or a specific regulatory filing related to internal controls, which aligns best with the 'Audit Report / Information' category (AR), as it is a formal report on internal controls, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER). Given the specific nature of the content (Internal Control Report), AR is the most appropriate classification among the provided options.
2025-06-26 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document text contains Japanese regulatory headers such as "【提出書類】確認書" (Filing Document: Confirmation Document) and references the "金融商品取引法" (Financial Instruments and Exchange Act). It explicitly states that the Representative Director confirms the appropriateness of the contents of the "有価証券報告書" (Securities Report) for the fiscal year ending March 31, 2025. A Securities Report in the Japanese context is equivalent to the US 10-K filing. Since this document is a confirmation statement *about* the Securities Report, and not the full report itself, it is closely related to the annual filing process. However, given the provided definitions, the closest fit for a comprehensive annual report is '10-K'. If this were purely an announcement of the 10-K release, it would be RPA/RNS. Since it is a formal confirmation document related to the annual filing, and the 10-K definition covers the 'Official yearly report covering company activity and full financial performance,' this confirmation is intrinsically linked to that annual filing. Given the context of a formal confirmation related to the annual filing (Securities Report), classifying it as 10-K is the most appropriate choice among the provided options, as it pertains directly to the annual reporting requirement. FY 2025
2025-06-26 Japanese
有価証券報告書－第61期(2024/04/01－2025/03/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuuka Shouken Houkokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the standard cover page with the company name (Sapporo Clinical Laboratory Inc.), the fiscal year (61st term, 2024-04-01 to 2025-03-31), and XBRL tagging data typical of official annual regulatory filings submitted to the Financial Services Agency (via the EDINET system). FY 2025
2025-06-26 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.